Resveratrol in cardiovascular health and disease

Annals of the New York Academy of Sciences

Volumn 1215, Issue 1, 2011, Pages 22-33

  Petrovski, Goran ^a   Gurusamy, Narasimman ^b   Das, Dipak K ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Atherosclerosis; Autophagy; Cardiovascular disease; Hormesis; Hypertension; Longevity genes; Myocardial regeneration; Resveratrol; Stem cells

Indexed keywords

RESVERATROL;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; AUTOPHAGY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; GLIOMA; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY;

EID: 78851472160     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05843.x     Document Type: Article

References (89)

1. Murray, C.J. & A.D. Lopez 1997. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349: 1436-1442.
2. Fontana, L. et al 2007. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am. J. Physiol. Endocrinol. Metab. 293: E197-E202.
3. Twisk, J.W. et al 1997. Which lifestyle parameters discriminate high- from low-risk participants for coronary heart disease risk factors. Longitudinal analysis covering adolescence and young adulthood. J. Cardiovasc. Risk 4: 393-400.
4. Bellisle, F. 2009. Infrequently asked questions about the Mediterranean diet. Public Health Nutr. 12: 1644-1647.
5. Willett, W.C. et al 1995. Mediterranean diet pyramid: a cultural model for healthy eating. Am. J. Clin. Nutr. 61: 1402S-1406S.
6. Renaud, S. & M. de Lorgeril 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
7. Sato, M., N. Maulik & D.K. Das 2002. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. N.Y. Acad. Sci. 957: 122-135.
8. Ghanim, H. et al 2010. An antiinflammatory and reactive oxygen species suppressive effects of an extract of polygonum cuspidatum containing resveratrol. J. Clin. Endocrinol. Metab. 91: E1-E8.
9. Roupe, K.A. et al 2006. Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 1: 81-101.
10. Berrougui, H. et al 2009. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 207: 420-427.
11. Gurusamy, N. et al Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc. Res. 86: 103-112.
12. Holthoff, J.H. et al 2010. Resveratrol, a dietary polyphenolic phytoalexin, is a functional scavenger of peroxynitrite. Biochem. Pharmacol. 80: 1260-1265.
13. Gurusamy, N. et al 2009. Cardioprotection by adaptation to ischaemia augments autophagy in association with BAG-1 protein. J. Cell Mol. Med. 13: 373-387.
14. Morselli, E. et al 2009. Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY). 1: 961-970.
15. Abeywardena, M.Y. 2003. Dietary fats, carbohydrates and vascular disease: Sri Lankan perspectives. Atherosclerosis. 171: 157-161.
16. Wildman, R.P. et al Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities. Obesity (Silver Spring). 2010 Aug 19 [Epub ahead of print] doi:.
17. Markus, M.A. & B.J. Morris 2008. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin. Interv. Aging 3: 331-339.
18. Nicholson, S.K., G.A. Tucker & J.M. Brameld 2008. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc. Nutr. Soc. 67: 42-47.
19. Della-Morte, D. et al 2009. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 159: 993-1002.
20. Altman, R. 2003. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb. J. 1: 4.
21. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
22. Vorchheimer, D.A. & V. Fuster 2001. Inflammatory markers in coronary artery disease: let prevention douse the flames. JAMA 286: 2154-2156.
23. Kinlay, S. et al 2001. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 104: 1114-1118.
24. Davignon, J. & P. Ganz 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32.
25. Rubbo, H. et al 2002. Antioxidant and diffusion properties of nitric oxide in low-density lipoprotein. Methods Enzymol. 359: 200-209.
26. Lin, M.T. et al 2003. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol. Pharmacol. 64: 1029-1036.
27. Zou, J.G. et al 2003. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int. J. Mol. Med. 11: 317-320.
28. O'Leary, K.A. et al 2004. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat. Res. 551: 245-254.
29. Wang, M.J. et al 2001. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J. Neuroimmunol. 112: 28-34.
30. Zhong, M. et al 1999. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 6: 79-84.
31. Culpitt, S.V. et al 2003. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58: 942-946.
32. Fremont, L., L. Belguendouz & S. Delpal 1999. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 64: 2511-2521.
33. Godichaud, S. et al 2000. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology 31: 922-931.
34. Olas, B. et al 2002. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb. Res. 107: 141-145.
35. Wang, Z. et al 2002. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int. J. Mol. Med. 9: 77-79.
36. Jang, J.H. & Y.J. Surh 2001. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat. Res. 496: 181-190.
37. Jang, D.S. et al 1999. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem. Pharmacol. 57: 705-712.
38. Martinet, W. & G.R. De Meyer 2009. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ. Res. 104: 304-317.
39. Clarke, M.C. et al 2006. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat. Med. 12: 1075-1080.
40. Liu, Z. et al 2005. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin. Exp. Pharmacol. Physiol. 32: 1049-1054.
41. Miatello, R., M. Cruzado & N. Risler 2004. Mechanisms of cardiovascular changes in an experimental model of syndrome X and pharmacological intervention on the renin-angiotensin-system. Curr. Vasc. Pharmacol. 2: 371-377.
42. Miatello, R. et al 2005. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens 18: 864-870.
43. Dammrich, J. & U. Pfeifer 1983. Cardiac hypertrophy in rats after supravalvular aortic constriction. II. Inhibition of cellular autophagy in hypertrophying cardiomyocytes. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 43: 287-307.
44. Decker, R.S. et al 1980. Lysosomal vacuolar apparatus of cardiac myocytes in heart of starved and refed rabbits. J. Mol. Cell. Cardiol. 12: 1175-1189.
45. Pfeifer, U. et al 1987. Short-term inhibition of cardiac cellular autophagy by isoproterenol. J. Mol. Cell Cardiol. 19: 1179-1184.
46. Sybers, H.D., J. Ingwall & M. DeLuca 1976. Autophagy in cardiac myocytes. Recent Adv. Stud. Cardiac. Struct. Metab. 12: 453-463.
47. Yamamoto, S. et al 2000. On the nature of cell death during remodeling of hypertrophied human myocardium. J. Mol. Cell Cardiol. 32: 161-175.
48. Rothermel, B.A. & J.A. Hill 2008. Autophagy in load-induced heart disease. Circ. Res. 103: 1363-1369.
49. Bolli, R. 2000. The late phase of preconditioning. Circ. Res. 87: 972-983.
50. Das, S. et al 2005. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol. 42: 281-289.
51. Das, S. et al 2005. Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 314: 762-769.
52. Das, S. et al 2005. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol. Heart Circ. Physiol. 288: H328-H335.
53. Das, S., C.G. Fraga & D.K. Das 2006. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic. Res. 40: 1066-1075.
54. Das, D.K. & N. Maulik 2006. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv. 6: 36-47.
55. Vidavalur, R. et al 2006. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp. Clin. Cardiol. 11: 217-225.
56. Thirunavukkarasu, M. et al 2008. White wine induced cardioprotection against ischemia-reperfusion injury is mediated by life extending Akt/FOXO3a/NFkappaB survival pathway. J. Agric. Food Chem. 56: 6733-6739.
57. Gurusamy N. et al 2010. Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium. J. Cell Mol. Med.14: 2235-2239.
58. Lekli, I. et al 2009. Co-ordinated autophagy with resveratrol and gamma-tocotrienol confers synergetic cardioprotection. J. Cell Mol. Med.
59. Chen, J.C. et al 2006. Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res. 26: 1237-1245.
60. Khan, A.A. et al. (Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am. J. Pathol. 177: 481-492.
61. Brakenhielm, E., R. Cao & Y. Cao 2001. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 15: 1798-1800.
62. Fesus, L., M.A. Demeny & G. Petrovski Autophagy Shapes Inflammation. Antioxid Redox Signal. 2010 Sep 2 [Epub ahead of print] doi:.
63. Petrovski, G. et al 2007. Phagocytosis of cells dying through autophagy evokes a pro-inflammatory response in macrophages. Autophagy 3: 509-511.
64. Lekli, I. et al Functional recovery of diabetic mouse hearts by glutaredoxin-1 gene therapy: role of Akt-FoxO-signaling network. Gene Ther. 17: 478-485.
65. Ramadori, G. et al 2009. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 150: 5326-5333.
66. Lekli, I. et al 2008. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol. 294: H859-H866.
67. Codogno, P. & A.J. Meijer 2005. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12(Suppl 2): 1509-1518.
68. Hayden, M.R. et al 2005. Type 2 diabetes mellitus as a conformational disease. Jop. 6: 287-302.
69. Wiseman, R.L. & W.E. Balch 2005. A new pharmacology-drugging stressed folding pathways. Trends Mol. Med. 11: 347-350.
70. Howitz, K.T. et al 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
71. Baur, J.A. & D.A. Sinclair 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
72. Mukherjee, S. et al 2009. Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic. Biol. Med. 46: 573-578.
73. Pearson, K.J. et al 2008. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8: 157-168.
74. Dillin, A. & J.W. Kelly 2007. Medicine. The yin-yang of sirtuins. Science 317: 461-462.
75. Minor, R.K. et al Dietary interventions to extend life span and health span based on calorie restriction. J. Gerontol. A Biol. Sci. Med. Sci. 65: 695-703.
76. Kaeberlein M. Resveratrol and rapamycin: are they anti-aging drugs? Bioessays 32: 96-99.
77. Weindruch, R. et al 2001. Microarray profiling of gene expression in aging and its alteration by caloric restriction in mice. J. Nutr. 131: 918S-923S.
78. Baur, J.A. et al 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
79. Valenzano, D.R. et al 2006. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 16: 296-300.
80. Partridge, L., S.D. Pletcher & W. Mair 2005. Dietary restriction, mortality trajectories, risk and damage. Mech. Ageing Dev. 126: 35-41.
81. Soleas, G.J., E.P. Diamandis & D.M. Goldberg 1997. Resveratrol: a molecule whose time has come? And gone? Clin. Biochem. 30: 91-113.
82. Collins, M.A. et al 2009. Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin. Exp. Res. 33: 206-219.
83. Chiueh, C.C., T. Andoh & P.B. Chock 2005. Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning-induced cardioprotection and neuroprotection. Ann. N.Y. Acad. Sci. 1042: 403-418.
84. Mattson, M.P. 2008. Hormesis defined. Ageing Res. Rev. 7: 1-7.
85. Prickett, C.D. et al 2004. Alcohol: Friend or Foe? Alcoholic Beverage Hormesis for Cataract and Atherosclerosis is Related to Plasma Antioxidant Activity. Nonlinearity Biol. Toxicol. Med. 2: 353-370.
86. Athar, M. et al 2009. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486: 95-102.
87. Bishayee, A. 2009. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila Pa) 2: 409-418.
88. Li, Y. et al Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 27: 1027-1041.
89. Sen, C.K. et al 2002. Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm. Ann. N.Y. Acad. Sci. 957: 239-249.